1,000th Patient Enrolls in Clinical Study Testing Infection Control Device

TYRX, a company that commercializes implantable combination drug and device products for infection control, announced that the 1,000th patient has been enrolled in the Citadel & Centurion clinical studies.

Citadel & Centurion are multi-center studies that are evaluating the use of TYRX's AIGISRx Antibacterial Envelope in patients who are at high risk for cardiovascular implantable electronic devices infection. High-risk patients are those whose current CIED is being replaced with an implantable cardioverter-defibrillator or a cardiac resynchronization therapy device accompanied by the AIGISRx.

The AIGISRx Antibacterial Envelope is a mesh device that holds a pacemaker or implantable cardioverter-defibrillator in place and is coated with antibiotic agents to reduce infections.

More Articles on TYRX:

Study Reveals TYRX Antibacterial Envelope Helps Lower Infections From Cardiac Devices
TYRX Announces ICD-9 Code for AIGISRx Antibacterial Envelope

TYRX Launches New Patient Education Website

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers